Key Highlights

  • Dyadic International (NASDAQ:DYAI) traded at USD 0.4232, up 7.71%, in pre-market trading on Wednesday, October 28, 2026. No company release dated on or just before that day was found, so the catalyst is unconfirmed.
  • For the quarter ended June 30, 2026, revenue was USD 961,138 against USD 966,630 a year earlier, and the net loss was USD 2,123,884, or USD 0.06 per share, according to the Wednesday, August 12, 2026 release.
  • Cash and investments stood at USD 4,794,798 on June 30, 2026, down from USD 8,587,289 at December 31, 2025, and management cited substantial doubt about the company's ability to continue as a going concern.
  • The share price is below USD 1.00, which is relevant to Nasdaq listing standards, and pre-market trading is thin, so the 7.71% move is a snapshot that can change before the open.

What Lies Behind the Move

Dyadic International (NASDAQ:DYAI) is a biotechnology company that develops recombinant proteins, meaning proteins produced by engineered cells, for biologics, food and nutrition. It traded at USD 0.4232 in pre-market trading on Wednesday, October 28, 2026, a gain of 7.71% on the snapshot. No company-specific announcement dated on or just before Wednesday, October 28, 2026 came with the move. The most recent published results are those for the second quarter, released on Wednesday, August 12, 2026. The advance appears consistent with thin pre-market liquidity and trading in a low-priced share, an inference rather than a stated cause.

How the Latest Results Frame the Move

Second quarter revenue was USD 961,138, a fall of 0.6% from USD 966,630, and six-month revenue was USD 2,072,094, according to the release of Wednesday, August 12, 2026. The net loss grew to USD 2,123,884 from USD 1,793,774, a loss of USD 0.06 per share in both years. Cash and investments dropped to USD 4,794,798 from USD 8,587,289 at December 31, 2025, and no financial guidance was offered. Operating highlights: pilot sales of recombinant transferrin and growth factors for cultivated meat, shipments to IBT Bioservices under an OEM distribution agreement and an estimated 80% productivity gain for transferrin at pilot scale. On Thursday, August 13, 2026 the company announced a registered direct offering and private placement of USD 2.9 million.

Downside Scenarios and Key Dates

Positives: early commercial sales across several protein products, grant-funded antibody programmes with the Gates Foundation and the extra capital raised in August 2026. Negatives: flat revenue, a widening loss, cash under USD 5 million at June 30, 2026 and the going concern warning, which signals that management doubts funds will last twelve months. Risks include dilution from more financing, Nasdaq listing compliance with the share price under USD 1.00 and slow uptake of cultivated meat inputs. Upcoming: third quarter results, any financing announcement, any Nasdaq notice and the Federal Reserve decision due later on Wednesday, October 28, 2026.

Where Things Stand

Dyadic International (NASDAQ:DYAI) rose on thin pre-market liquidity, since no company announcement dated October 28, 2026 has surfaced. The figure that matters most is cash and investments of USD 4,794,798 at June 30, 2026, set against a quarterly net loss of USD 2,123,884. Upcoming catalysts are the third quarter report, any further financing or Nasdaq correspondence and the Federal Reserve decision due later on Wednesday, October 28, 2026. Pre-market prices are snapshots and can change, and this is not investment advice.